Results 11 to 20 of about 145,467 (273)

Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve.

NEJM Evidence, 2023
Apixaban, Warfarin, and On-X Mechanical Aortic ValvesAlthough vitamin K antagonists are the only oral anticoagulants approved with mechanical heart valves, this trial examined whether apixaban could be safely used in patients with an On-X mechanical ...
Tracy Y. Wang, L. Svensson, Jun Wen, A. Vekstein, Marc W. Gerdisch, V. Rao, M. Moront, D. Johnston, R. Lopes, Alma Chavez, M. Ruel, E. Blackstone, Richard C. Becker, V. Thourani, J. Puskas, H. Al-Khalidi, D. G. Cable, J. Elefteriades, A. Pochettino, J. Wolfe, A. Graeve, Ibrahim S Sultan, Ashraf A. Sabe, H. Michelena, J. Alexander   +24 more
semanticscholar   +1 more source

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Blood Advances, 2021
Key Points The primary outcome, stroke, occurred in 6 of 23 patients randomized to apixaban compared with 0 of 25 patients randomized to warfarin. This study with limitations suggests that apixaban is not an equitable substitute for warfarin to prevent ...
S. Woller, S. Stevens, David A Kaplan, Tzu‐Fei Wang, D. Branch, Danielle Groat, E. Wilson, Brent P. Armbruster, V. Aston, J. Lloyd, M. Rondina, C. Elliott   +11 more
semanticscholar   +1 more source

Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi.

JAMA cardiology, 2020
Importance Left ventricular (LV) thrombi can arise in patients with ischemic and nonischemic cardiomyopathies. Anticoagulation is thought to reduce the risk of stroke or systemic embolism (SSE), but there are no high-quality data on the effectiveness of ...
A. Robinson, C. Trankle, G. Eubanks, C. Schumann, P. Thompson, Ryan Wallace, S. Gottiparthi, Benjamin K Ruth, C. Kramer, M. Salerno, K. Bilchick, C. Deen, M. Kontos, J. Dent   +13 more
semanticscholar   +1 more source

An Atypical Case of Warfarin-Induced Skin Necrosis

Clinical Practice and Cases in Emergency Medicine, 2017
Skin necrosis is a relatively rare, potentially fatal side effect of warfarin. It is most commonly reported within 10 days of initiation of therapy in warfarin-naïve patients.
Lindsay R. Sklar, Anne Messman
doaj   +1 more source

Standardized warfarin monitoring decreases adverse drug reactions

BMC Family Practice, 2019
Background While warfarin is the most commonly prescribed medication to prevent thromboembolic disorders, the risk of adverse drug reactions (ADR) poses a serious concern.
Lisa B. E. Shields, Paula Fowler, Diane M. Siemens, Douglas J. Lorenz, Kenneth C. Wilson, Steven T. Hester, Joshua T. Honaker   +6 more
doaj   +1 more source

Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]

, 2016
BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core   +2 more sources

Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery

Research in Cardiovascular Medicine, 2015
Background: Warfarin is an anticoagulant and is widely used for the prevention of thromboembolic events. Genetic variants of the enzymes that metabolize warfarin, i.e.
Avisa Tabib, Babak Najibi, Mohammad Dalili, Ramin Baghaei, Behzad Poopak   +4 more
doaj   +1 more source

Bleeding Incidence in Patients Administered with Warfarin at Secondary Hospitals in Yogyakarta Province

Indonesian Journal of Pharmacy, 2020
Warfarin is an oral anticoagulant most-commonly prescribed for prevention and treatment of thromboembolism. It is widely acknowledged that warfarin has both narrow therapeutic index and various drug-food interactions, thus carrying the risk of ...
Vitarani D.A Ningrum, Sufiyah Sufiyah, Irine Dyah Widyastuti, Bacrie Sufriyanto Yusuf, Wahyudin Dullah   +4 more
doaj   +1 more source

The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study. [PDF]

PLoS ONE, 2016
Warfarin oral anticoagulant therapy (OAT) requires regular and frequent drug adjustment monitored by INR. Interindividual variability, drug and diet interferences, and genetics (VKORC1 and CYP2C9) make the maintenance/reaching of stable INR a not so easy
Donato Gemmati, Francesco Burini, Anna Talarico, Matteo Fabbri, Cesare Bertocco, Marco Vigliano, Stefano Moratelli, Antonio Cuneo, Maria Luisa Serino, Francesco Maria Avato, Veronica Tisato, Rosa Maria Gaudio   +11 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source